Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Central Nervous System (CNS) Stimulant Drugs Market Insights, Forecast to 2026

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Central Nervous System (CNS) Stimulant Drugs Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Central Nervous System (CNS) Stimulant Drugs Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate by Type
    • 1.4.2 Amphetamine
    • 1.4.3 Cocaine
    • 1.4.4 Caffeine
    • 1.4.5 Others
  • 1.5 Market by Application
    • 1.5.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate by Application
    • 1.5.2 Attention Deficit Hyperactivity Disorder (ADHD)
    • 1.5.3 Narcolepsy
    • 1.5.4 Others
  • 1.6 Coronavirus Disease 2019 (Covid-19): Central Nervous System (CNS) Stimulant Drugs Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Central Nervous System (CNS) Stimulant Drugs Industry
      • 1.6.1.1 Central Nervous System (CNS) Stimulant Drugs Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Central Nervous System (CNS) Stimulant Drugs Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Central Nervous System (CNS) Stimulant Drugs Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Executive Summary

  • 2.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size Estimates and Forecasts
    • 2.1.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue 2015-2026
    • 2.1.2 Global Central Nervous System (CNS) Stimulant Drugs Sales 2015-2026
  • 2.2 Central Nervous System (CNS) Stimulant Drugs Market Size by Region: 2020 Versus 2026
    • 2.2.1 Global Central Nervous System (CNS) Stimulant Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Central Nervous System (CNS) Stimulant Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Central Nervous System (CNS) Stimulant Drugs Competitor Landscape by Players

  • 3.1 Central Nervous System (CNS) Stimulant Drugs Sales by Manufacturers
    • 3.1.1 Central Nervous System (CNS) Stimulant Drugs Sales by Manufacturers (2015-2020)
    • 3.1.2 Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Central Nervous System (CNS) Stimulant Drugs Revenue by Manufacturers
    • 3.2.1 Central Nervous System (CNS) Stimulant Drugs Revenue by Manufacturers (2015-2020)
    • 3.2.2 Central Nervous System (CNS) Stimulant Drugs Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Central Nervous System (CNS) Stimulant Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Central Nervous System (CNS) Stimulant Drugs Revenue in 2019
    • 3.2.5 Global Central Nervous System (CNS) Stimulant Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Central Nervous System (CNS) Stimulant Drugs Price by Manufacturers
  • 3.4 Central Nervous System (CNS) Stimulant Drugs Manufacturing Base Distribution, Product Types
    • 3.4.1 Central Nervous System (CNS) Stimulant Drugs Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Central Nervous System (CNS) Stimulant Drugs Product Type
    • 3.4.3 Date of International Manufacturers Enter into Central Nervous System (CNS) Stimulant Drugs Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size by Type (2015-2020)
    • 4.1.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2015-2020)
    • 4.1.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2015-2020)
    • 4.1.3 Central Nervous System (CNS) Stimulant Drugs Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue Forecast by Type (2021-2026)
    • 4.2.3 Central Nervous System (CNS) Stimulant Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Central Nervous System (CNS) Stimulant Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Breakdown Data by Application (2015-2026)

  • 5.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size by Application (2015-2020)
    • 5.1.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2015-2020)
    • 5.1.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2015-2020)
    • 5.1.3 Central Nervous System (CNS) Stimulant Drugs Price by Application (2015-2020)
  • 5.2 Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Central Nervous System (CNS) Stimulant Drugs Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Central Nervous System (CNS) Stimulant Drugs by Country
    • 6.1.1 North America Central Nervous System (CNS) Stimulant Drugs Sales by Country
    • 6.1.2 North America Central Nervous System (CNS) Stimulant Drugs Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Type
  • 6.3 North America Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Central Nervous System (CNS) Stimulant Drugs by Country
    • 7.1.1 Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country
    • 7.1.2 Europe Central Nervous System (CNS) Stimulant Drugs Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Type
  • 7.3 Europe Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Central Nervous System (CNS) Stimulant Drugs by Region
    • 8.1.1 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Region
    • 8.1.2 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Type
  • 8.3 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Central Nervous System (CNS) Stimulant Drugs by Country
    • 9.1.1 Latin America Central Nervous System (CNS) Stimulant Drugs Sales by Country
    • 9.1.2 Latin America Central Nervous System (CNS) Stimulant Drugs Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Type
  • 9.3 Central & South America Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs by Country
    • 10.1.1 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country
    • 10.1.2 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Type
  • 10.3 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Astellas Pharma
    • 11.1.1 Astellas Pharma Corporation Information
    • 11.1.2 Astellas Pharma Description, Business Overview and Total Revenue
    • 11.1.3 Astellas Pharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Products Offered
    • 11.1.5 Astellas Pharma Recent Development
  • 11.2 Biogen
    • 11.2.1 Biogen Corporation Information
    • 11.2.2 Biogen Description, Business Overview and Total Revenue
    • 11.2.3 Biogen Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Biogen Central Nervous System (CNS) Stimulant Drugs Products Offered
    • 11.2.5 Biogen Recent Development
  • 11.3 Celltech
    • 11.3.1 Celltech Corporation Information
    • 11.3.2 Celltech Description, Business Overview and Total Revenue
    • 11.3.3 Celltech Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Celltech Central Nervous System (CNS) Stimulant Drugs Products Offered
    • 11.3.5 Celltech Recent Development
  • 11.4 Eli Lilly and Company
    • 11.4.1 Eli Lilly and Company Corporation Information
    • 11.4.2 Eli Lilly and Company Description, Business Overview and Total Revenue
    • 11.4.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Products Offered
    • 11.4.5 Eli Lilly and Company Recent Development
  • 11.5 GlaxoSmithKline
    • 11.5.1 GlaxoSmithKline Corporation Information
    • 11.5.2 GlaxoSmithKline Description, Business Overview and Total Revenue
    • 11.5.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Products Offered
    • 11.5.5 GlaxoSmithKline Recent Development
  • 11.6 Johnson and Johnson
    • 11.6.1 Johnson and Johnson Corporation Information
    • 11.6.2 Johnson and Johnson Description, Business Overview and Total Revenue
    • 11.6.3 Johnson and Johnson Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Products Offered
    • 11.6.5 Johnson and Johnson Recent Development
  • 11.7 Merck
    • 11.7.1 Merck Corporation Information
    • 11.7.2 Merck Description, Business Overview and Total Revenue
    • 11.7.3 Merck Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Merck Central Nervous System (CNS) Stimulant Drugs Products Offered
    • 11.7.5 Merck Recent Development
  • 11.8 Novartis
    • 11.8.1 Novartis Corporation Information
    • 11.8.2 Novartis Description, Business Overview and Total Revenue
    • 11.8.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Novartis Central Nervous System (CNS) Stimulant Drugs Products Offered
    • 11.8.5 Novartis Recent Development
  • 11.9 Perdue Pharma
    • 11.9.1 Perdue Pharma Corporation Information
    • 11.9.2 Perdue Pharma Description, Business Overview and Total Revenue
    • 11.9.3 Perdue Pharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Products Offered
    • 11.9.5 Perdue Pharma Recent Development
  • 11.10 Pfizer
    • 11.10.1 Pfizer Corporation Information
    • 11.10.2 Pfizer Description, Business Overview and Total Revenue
    • 11.10.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Pfizer Central Nervous System (CNS) Stimulant Drugs Products Offered
    • 11.10.5 Pfizer Recent Development
  • 11.1 Astellas Pharma
    • 11.1.1 Astellas Pharma Corporation Information
    • 11.1.2 Astellas Pharma Description, Business Overview and Total Revenue
    • 11.1.3 Astellas Pharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Products Offered
    • 11.1.5 Astellas Pharma Recent Development
  • 11.12 Sanofi
    • 11.12.1 Sanofi Corporation Information
    • 11.12.2 Sanofi Description, Business Overview and Total Revenue
    • 11.12.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Sanofi Products Offered
    • 11.12.5 Sanofi Recent Development
  • 11.13 Shire
    • 11.13.1 Shire Corporation Information
    • 11.13.2 Shire Description, Business Overview and Total Revenue
    • 11.13.3 Shire Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 Shire Products Offered
    • 11.13.5 Shire Recent Development
  • 11.14 Takeda Pharmaceuticals
    • 11.14.1 Takeda Pharmaceuticals Corporation Information
    • 11.14.2 Takeda Pharmaceuticals Description, Business Overview and Total Revenue
    • 11.14.3 Takeda Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.14.4 Takeda Pharmaceuticals Products Offered
    • 11.14.5 Takeda Pharmaceuticals Recent Development
  • 11.15 Thermo Fisher Scientific
    • 11.15.1 Thermo Fisher Scientific Corporation Information
    • 11.15.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue
    • 11.15.3 Thermo Fisher Scientific Sales, Revenue and Gross Margin (2015-2020)
    • 11.15.4 Thermo Fisher Scientific Products Offered
    • 11.15.5 Thermo Fisher Scientific Recent Development

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Central Nervous System (CNS) Stimulant Drugs Market Estimates and Projections by Region
    • 12.1.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue Forecast by Regions 2021-2026
  • 12.2 North America Central Nervous System (CNS) Stimulant Drugs Market Size Forecast (2021-2026)
    • 12.2.1 North America: Central Nervous System (CNS) Stimulant Drugs Sales Forecast (2021-2026)
    • 12.2.2 North America: Central Nervous System (CNS) Stimulant Drugs Revenue Forecast (2021-2026)
    • 12.2.3 North America: Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Central Nervous System (CNS) Stimulant Drugs Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Central Nervous System (CNS) Stimulant Drugs Sales Forecast (2021-2026)
    • 12.3.2 Europe: Central Nervous System (CNS) Stimulant Drugs Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Central Nervous System (CNS) Stimulant Drugs Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Central Nervous System (CNS) Stimulant Drugs Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Central Nervous System (CNS) Stimulant Drugs Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Central Nervous System (CNS) Stimulant Drugs Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Central Nervous System (CNS) Stimulant Drugs Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Central Nervous System (CNS) Stimulant Drugs Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Central Nervous System (CNS) Stimulant Drugs Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter’s Five Forces Analysis
  • 13.5 Primary Interviews with Key Central Nervous System (CNS) Stimulant Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Central Nervous System (CNS) Stimulant Drugs Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source

    Central Nervous System (CNS) Stimulant Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Central Nervous System (CNS) Stimulant Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Central Nervous System (CNS) Stimulant Drugs market is segmented into
    Amphetamine
    Cocaine
    Caffeine
    Others

    Segment by Application, the Central Nervous System (CNS) Stimulant Drugs market is segmented into
    Attention Deficit Hyperactivity Disorder (ADHD)
    Narcolepsy
    Others

    Regional and Country-level Analysis
    The Central Nervous System (CNS) Stimulant Drugs market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Central Nervous System (CNS) Stimulant Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Central Nervous System (CNS) Stimulant Drugs Market Share Analysis
    Central Nervous System (CNS) Stimulant Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Central Nervous System (CNS) Stimulant Drugs business, the date to enter into the Central Nervous System (CNS) Stimulant Drugs market, Central Nervous System (CNS) Stimulant Drugs product introduction, recent developments, etc.
    The major vendors covered:
    Astellas Pharma
    Biogen
    Celltech
    Eli Lilly and Company
    GlaxoSmithKline
    Johnson and Johnson
    Merck
    Novartis
    Perdue Pharma
    Pfizer
    Roche
    Sanofi
    Shire
    Takeda Pharmaceuticals
    Thermo Fisher Scientific

    Buy now